Background: The increasing armamentarium of disease-modifying therapies in multiple sclerosis is accompanied by potentially severe adverse effects. The cell-adhesion molecule CD62L, which facilitates leukocyte extravasation, has been proposed as a predictive marker for treatment tolerability. However, pre-analytical procedures might impact test results, thereby limiting its clinical usability. Whether the immediate analysis of CD62L expression of peripheral blood mononuclear cells can aid treatment decision making is yet unclear. Objective: To investigate the effect of various disease-modifying therapies in multiple sclerosis on CD62L expression of CD3 þ CD4 þ peripheral blood mononuclear cells in freshly collected blood samples. Methods: We collected peripheral blood samples from patients with clinically isolated syndrome and multiple sclerosis (baseline/follow up n ¼ 234/n ¼ 98) and healthy controls (n ¼ 51).
Introduction
An increasing number of highly effective disease modifying therapies (DMTs) are available in multiple sclerosis (MS). Nevertheless, both treatment response and the occurrence of potentially severe side effects in individual patients remain highly unpredictable. 1 Therefore, a strong clinical need exists for body fluid markers that can aid in treatment decision making in terms of efficacy and tolerability. 1 CD62L, or L-selectin, is a cell adhesion molecule expressed on all leukocytes, which facilitates lymphocyte extravasation and homing of naive T cells to peripheral lymphoid organs. The presence of CD62L ligands on oligodendrocytes and myelin in the central nervous system (CNS) might furthermore mediate leukocyte targeting to myelinated axons, e.g. in demyelinating diseases. 2 Recently, it was suggested that the expression of CD62L on CD3 þ CD4 þ peripheral blood mononuclear cells (PBMCs) is decreased with the use of different DMTs in MS, especially natalizumab and fingolimod. [3] [4] [5] It was hypothesized that as a secondary result of this dysfunctional immune status, immune cells in these patients are not able to suppress viral activity as sufficiently, allowing viruses to induce disease. On this basis, CD62L expression could potentially serve as a risk marker for the development of viral infection under the use of DMTs. 3, 6 Currently, the reduction of CD62L due to DMT usage has mainly been associated with the development of progressive multifocal leukoencephalopathy (PML), a severe John Cunningham (JC) virus-induced demyelinating disease. 3, 4, [6] [7] [8] [9] Notably, most studies towards CD62L in MS were performed on cryopreserved PBMCs, for which a pre-analytical procedure is required, which has been shown to impact the test results. 1, 6, 8, 10 Two studies postulated that the CD62L expression is solely an indicator of immune cell stress and subsequent decreased cellular integrity caused by the freeze/thaw procedure. 6, 10 The clinical applicability of CD62L as a treatment risk marker may be limited due to the influence of sample quality and the potential requirement of the pre-analytical steps, which may further differ among laboratories. Nevertheless, it is not yet clear if immediate measurement of CD62L may yield comparable results in prognosticating treatment tolerability, and how expression of this surface marker in freshly collected samples may be altered by various DMTs. Therefore, we here aimed to determine longitudinal CD62L expression of CD3 þ CD4 þ PBMCs in freshly collected whole blood in MS patients using different types of DMTs, and compare it to healthy controls.
Patients, materials and methods
This study was approved by the ethics committee of the Medical University of Graz, Austria. All participants gave written informed consent.
Patients and controls
We included consecutive patients (n ¼ 234) who were seen at the MS outpatient clinic of the Department of Neurology, Medical University of Graz, during regular clinical visits between March and December 2015, and met the following criteria: 1) diagnosis with clinically isolated syndrome (CIS) suggestive of MS, or definite MS, according to available criteria at time of inclusion; 11, 12 2) availability of one or multiple fresh full blood samples; and 3) availability of detailed clinical data.
Healthy controls (n ¼ 51) consisted of volunteers who were seen at the 'Area health insurance of Graz' between April and October 2015, and met the following criteria: 1) legal age and maturity; 2) no diagnosis with neoplastic disease, acute or chronic infections, autoimmune diseases, acute or chronic diseases with organ damage, pregnancy, or severe anaemia (Hb < 9 mg/dl); and 3) availability of a freshly taken full blood sample.
Clinical assessment and follow up Demographic and clinical data of patients were recorded at every visit by experienced neurologists. These included age, gender, age at disease onset, occurrence of relapses, degree of disability as determined by the Expanded Disability Status Scale (EDSS) score, 13 and medication. 
Results

Cohort description
Demographic and clinical data of all subjects included are listed in Table 1 . At time of the first analysis, 181/234 patients received long-term DMT:
, interferon beta (n ¼ 90) and glatiramer acetate (n ¼ 30). Longitudinal blood samples were obtained in 98 patients (up to a total of seven samples per patient; total time interval between baseline and last sample collection median 113, interquartile range (IQR) 78-163 days), see Table  2 and Table 3 for data per subgroup.
For the entire patient group (n ¼ 234), the clinical follow-up time was median 9.5, IQR 6.2-13.4 months upon baseline sampling. Table 2 . CD62L expression of study subjects per patient subgroup at baseline and follow up. Table 3 . CD62L expression of study subjects per DMT subgroup at baseline and follow up. (Figure 1a ).
Longitudinal CD62L expression CD62L expression showed no significant temporal dynamics in longitudinal samples considering all patients, and in patients without switching DMT during the sampling interval (Table 2 and 3, Figure 1b ). Effects of DMT on PBMC CD62L expression were visible in longitudinal samples of patients who did switch from natalizumab to fingolimod therapy (Figure 1c ). CD62L expression was increased upon natalizumab withdrawal in two patients (natalizumab treated until 5.9 and 6.8 years, respectively). A rapid and considerable decrease in CD62L expression was visible in six patients upon fingolimod initiation.
Associations with demographic and clinical data
No gender or age-related effects on CD62L expression were seen. Spearman correlations were not significant for baseline CD62L expression with age We also did not find any significant correlations of CD62L expression with other clinical data, i.e. therapy duration, EDSS at time of sampling and during follow up, and the annualised relapse rate.
None of the patients included developed PML during the study follow-up time. Considering only natalizumab-treated patients, there was no significant difference between JC virus-antibody seronegative (n ¼ 15) and seropositive (n ¼ 11) patients regarding CD62L expression at the time of the first measurement. A total of six natalizumab treated patients did change their therapy during the total clinical follow-up period (total treatment time natalizumab median 5.8, IQR 5.3-6.9 years; change to dimethyl fumarate n ¼ 1, fingolimod n ¼ 1, no DMT n ¼ 4). Patients who switched from natalizumab during follow up had similar CD62L expression at baseline compared to patients who stayed on natalizumab.
Discussion
In this study we investigated the CD62L expression of CD3 þ CD4 þ PBMCs in freshly collected whole blood during the use of various DMTs in MS, using direct FACS flow cytometry. We show that the CD62L expression of fresh CD3 þ CD4
þ PBMCs is decreased with natalizumab and even more with fingolimod treatment, whereas increased levels are found in dimethyl fumarate-treated patients when compared to patients treated with other/no DMTs and healthy controls.
The direction of changes in CD62L expression with natalizumab and fingolimod is comparable to previous results on cryopreserved CD4 þ PBMCs. 3, 4 Treatment with fingolimod causes a selective retention of predominantly CD4 þ , and subsidiarily CD8 þ , naive T cells and central memory T cells (both CD62L þ ) in the lymphoid tissues, without affecting effector memory T cells (CD62L À ) or inducing lymphocyte destruction. 5, 14, 15 As a result, the overall count of peripheral blood lymphocytes is reduced under fingolimod, in particular that of CD62L þ lymphocytes. Our results on dimethyl fumarate are in line with previous findings, showing that expanded CD4 þ CD62L þ expression was found in fresh blood samples of fumarate-treated MS patients compared to non-treated patients and healthy controls. 16 It is thought that this immunophenotypical shift consists of a reduction in the number of effector memory T cells (CD62L À ) and a relative increase of naive T cells (CD62L þ ). The underlying mechanisms leading to alterations in CD62L expression under various DMTs are debated and further research into lymphocyte differentiation and redistribution is needed to better understand the information conveyed by this marker.
Results from a small subcohort of patients who switched their treatment during the time interval of longitudinal sampling show that CD62L expression increases after natalizumab withdrawal, and decreases rapidly upon fingolimod initiation. This indicates the hampering effect of these DMTs on CD62L expression of CD3 þ CD4 þ PBMCs, and the ability for CD62L recovery after DMT withdrawal. Similar results were shown in a recent study on CD4 þ and CD8 þ PBMCs in freshly collected blood samples (processed within 6 hours of collection, subsequent analysis within 12 hours). 17 Our longitudinal data further demonstrate temporal stability of CD62L expression in patients who were untreated or did not change their DMT use during multiple sampling. Until now, the invariability of CD62L expression was merely indicated for longterm natalizumab treatment in MS. 4, 17 It has been suggested that CD62L expression of PBMCs might be used as a risk-stratification marker for PML. 3, 4, [6] [7] [8] PML is usually a fatal opportunistic infection of the CNS caused by the JC virus, which appears most frequently in natalizumab-treated patients, 18 although cases have also been described during treatment with fingolimod 1 and dimethyl fumarate. 19 The association between CD62L and PML is not completely understood; it has been suggested that the general loss of T cells (lymphocytopenia), or the differential effect on T cell subsets by DMTs could be the most important risk factor. 1, 19 Some studies showed decreased CD62L expression in pre-PML compared to non-PML natalizumab-treated patients when using cryopreserved PBMCs. 3, 6, 8 However, these data could not be confirmed in another study 10 and in a sub-cohort using freshly isolated PBMCs. 6 This discrepancy could be caused by assay variability due to pre-analytical procedures, i.e. the freeze/thaw procedure, 1, 6, 10 or the sample storage protocol handled prior to the cell surface assessment. 8 Here we solely analysed freshly collected blood samples within 1 hour of sampling to prevent any potential preanalytical bias.
Overall, we could demonstrate feasibility to detect significant alterations in CD62L expression of CD3 þ CD4 þ PBMCs with various DMTs when measured in fresh blood samples, without laborious preanalytical steps. We found CD62L to be temporally stable, but differentially regulated with the use of various DMTs. The clinical significance of these findings is not yet clear. Future research is warranted to investigate if CD62L, when immediately measured, may serve as a biomarker for risk stratification of DMT side effects in MS, and as a possible marker for treatment response or disease activity/ progression over a longer time. Flow cytometry is a widely accessible method, and the protocol proposed here could readily be implemented in clinical practice. 
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